Summary.-Serum angiotensin-converting enzyme (SACE) in 141 patients with newly detected primary lung cancer was 22-1 + 6-1 nmol/ml/min (mean + s.d.); lower than in healthy controls (24.4 + 6-2 nmol/ml/min, P <0.02). No correlation was found between SACE and sex, age, site of cancer, histological type, or lung function.
A PROBLEM in evaluating lung-cancer patients for surgical treatment is that prognosis is poor, despite considerable technical and pharmacological improvement (Br. Med. J., Editorial, 1975) . Thus even if a tumour is judged to be resectable on preoperative examination, the patient is often inoperable at thoracotomy; and even if the cancer is radically removed, the relapse rate and frequency of clinically unsuspected distant spread of cancer is high.
Since even an explorative thoracotomy is not without risk and discomfort for the patient, improvement in the methods for selecting patients for operation would be valuable.
Angiotensin-converting enzyme (ACE) is a membrane-bound glycoprotein found in endothelium throughout the body, but mainly in the lung vasculature. Here it has been demonstrated in pinocytic vesicles of the capillary endothelium (Ryan et al., 1975) . The physiological role of ACE is at least two-fold: (1) to convert inactive angiotensin I into the vasopressor angiotensin II, and (2) to participate in the degradation of bradykinin (hence the synonymous II "kininase") (Soffer, 1976) . Thus, the enzyme plays an important part in the metabolic and paraendocrine functions of the lung (Bakhle & Vane, 1977) .
The level of serum-ACE (SACE) in lung cancer is generally reported to be low. Although statistical significance was not reached in an earlier series of 40 patients from our Department (R0mer, 1 980b) , significantly lowered SACE in lung cancer has been reported by other investigators (Ashutosh & Keighley, 1976; Gronhagen-Riska, 1979; Lieberman et al., 1979; Silverstein et al., 1977) . In only one paper a rather high SACE was noted (Turton et al., 1979) . However, detailed analysis was not possible because most of the series were small, and had insufficient clinical data.
The aim of the present study is to examine the hypothesis that the preoperative level of SACE is associated with prognosis in lung cancer, expressed by the number of patients who were referred for surgery, radically operated and free of cancer, respectively.
METHODS
Patients.-A total of 150 patients with biopsy-proven, newly detected primary lung cancer were examined (Table I ). All patients were untreated at the time of examination except for one on prednisone. Kidney funiction was normal in all patients but one. Sex, age, site of cancer and pathology are shown in Table II. The subdivision of the patients is shown in Table I . Of 150 patients nine were only used for examination of SACE pre-and postoperatively. They were examined late in the study, and were excluded from other calculations because of lack of follow-up time. Thus, the observations on clinical variables and prognosis were made on 141 consecutive patients. Of these, 54 (38%) were referred for surgery and underwent operation (Group A). Of these the operation was radical (tumour completely removed without residual cancer) in 33 (61 %) (Group B) . The radically operated and surviving patients were followed for 8-22 months (mean 16). Relapse (local recurrence or distant metastases) occurred in 8 of these, leaving 25 patients (18%) free of cancer or "cured" (Group C). Eight of these died from postoperative complications. Thus, 17 were alive and free of cancer during the period of observation. Number of deaths was only quoted in radically operated patients without relapse of cancer. Among radically operated patients, none were treated with radiation or chemotherapy. Any patient was lost from follow-up when he had relapse or died, and the results of radiation and chemotherapy were not considered.
Mediastino-bronchoscopy was performed in all patients who were not obviously inoperable. Liver and bone scans were routinely used as screening methods for extrapulmonary metastasis. Lung function was examined with respect to arterial blood oxygen and carbon dioxide, pH, lung capacities and volumes, airway resistance and diffusion capacity.
Evaluation and treatment, and determination of SACE were done independently.
Analysis.-SACE was analyzed using the method of Cushman & Cheung (1971) as modified by Lieberman (1975 Lieberman ( , 1976 (Bradford Hill, 1971) . Correlation was tested with the Spearman's rho. SACE was expressed as mean + 1 s.d. The significance level was 5%.
RESULTS

SACE in lung cancer and healthy controls
Among 141 patients with lung cancer SACE was 22-1 + 6-1 nmol/ml/min (range 7-0-33-7). This was lower than the figure for healthy persons (P < 0-02). No correlation was found between age and SACE in persons with lung cancer or the controls. Four patients with lung cancer had sarcoid-like non-caseating epithelioid granulomas in lymph nodes draining cancer. SACE in these patients was 16-2-29-9 nmol/ml/min. Clinical features and outcome These are shown in Table II . No association between outcome and sex, age or site of cancer was found. Patients with anaplastic carcinoma showed a different pattern from those with non-anaplastic neoplasms, because a smaller proportion was found suitable for surgery (19% vs 48%). Patients who died or had relapse of cancer after operation Among the 33 patients radically operated, postoperative death not due to relapse occurred in 8 (24%) within 2-12 weeks (9) 12 (26) 6 (23) 3 (14) (mean 6). Another 8 patients had relapse after 2-40 weeks (mean 21). SACE in the former group was significantly higher than in the latter (Table I) .
The patients who died from postoperative complications (and without evidence of cancer) were not included in the observed prognosis of cancer (Tables II, III  and V) (16) 37 (32) 8 (32) 2 (33) 14 (41) 18 (26) 11 (34) 40 (35) 19 (16) 8 (32) 6 (24) 2 (33) 2 (33) 7 (21) 4 (12) 30 (44) 12 (17) (20) 5 (19) 1 (4) 12 (26) 19 (40) 17 (37) 12 (26) 5 (19) 12 (16) 11 (50) 5 (23) 12 (15) 13 (22) 8 (17) 
( (0) (Table IV) . Thus, the results were:
(3) Nobody with SACE < 16-0 units was cured, though 7/23 (30%o) were judged operable at preoperative evaluation; (4) the proportion cured was significantly smaller in patients with SACE <16-0 units (0/23=0%, 950o confidence limits 0-15) than in patients with SACE > 28*2 units (9.2/25 = 3666%, confidence limits 18-58);
(5) the proportion of operated patients who were cured was correlated with increasing SACE level (X2 6X962, d.f.=1, P < 0X01); (6) the proportion of all patients cured was strongly correlated to increasing enzyme level (X2 11X712, d.f.= 1, P < 0-001);
(7) The proportion cured and surviving (n = 17) out of all patients was also correlated with increasing enzyme levels (X2 4X714, d.f. = 1, P < 0-05).
SACE and clinical features versus prognosis
Combining data in Tables II and III 
Course ofSACE in incurable patients
In 8 untreated unoperated patients, SACE was analysed twice or more, with an interval of weeks to months (mean 4 months). The enzyme activity decreased in all cases, from a SACE of 20'9 + 8-9 units at first examination to 1841 + 8-2 units at last examination (P < 002). The decline was about 3% a month, and regression analysis showed a relationship between length oftime between blood samples and the percentage decline of SACE (P < 0*02).
Two inoperable patients who were treated with chemotherapy and irradia- tion showed an increasing enzyme activity after therapy and tumour regression. SACE increased from ] &8 to 26-5 units and from 21 8 to 24*0 units, respectively. 
SACE in patients undergoing operation
The relationship between surgical procedures, SACE and outcome is shown in Table V .
In an additional 9 patients, SACE was analysed before operation and 3 or 6 days after operation. SACE showed a small decline from 16-7 + 4-6 units preoperatively to 14-5 + 3-5 postoperatively (P < 0 02) independently of the extent and type of operation (Fig. 2) .
DISCUSSION
The present results have demonstrated a strong association between preoperative SACE level and outcome in patients with lung cancer, suggesting that low SACE may be an indicator of inoperability. Thus, nobody with SACE lower than the mean for lung cancer -1 s.d. was cured.
Both a time-dependent decreasing SACE in inoperable patients, an increasing SACE in patients undergoing successful chemotherapy, and the relationship between enzyme levels and prognosis of cancer, suggest an association between enzyme level and disease spread. The findings were independent of age, sex, site of cancer and histological type, and mean SACE was not correlated to pulmonary function. Furthermore, despite a significant correlation between SACE and operability at preoperative evaluation, the strongest correlation was seen after up to 22 months of observation. These results suggest that factors contributing to the low SACE may in part be independent of those noted at preoperative evaluation, e.g. size and spread of cancer, histology, age, general condition, pulmonary function, etc.
The reason for these findings remains speculative. With respect to the endothelial localization of the enzyme, a low SACE could be caused by spread of cancer into the pulmonary vasculature, followed by a decreased enzyme formation, although the discrete fall in SACE after operation (including two patients undergoing total pneumectomy) suggest that this purely mechanical hypothesis is not the only explanation. An inhibition of enzyme formation by tumour-produced enzyme inhibitors or by pulmonary hypoxia (Bedrossian et al., 1978; Stalcup et al., 1979) was another possible explanation. However, if enzyme inhibition was involved, increased SACE would be expected after removal of cancer; but in fact a slight decrease was seen. Furthermore, no correlation was found between SACE and arterial gas tensions.
Among patients with lung cancer as a whole, a slight (but significant) lower mean SACE was found when compared with healthy controls. This is in agreement with previous reports on lung cancer. A decreased SACE level has also been found in malignant lymphoproliferative and haematological disorders in which SACE was also associated with prognosis, though not so regularly as observed in lung cancer (R0mer & Emmertsen, 1980) . With regard to other lung diseases, measurement of SACE has been mostly used in sarcoidosis (Lancet, Editorial, 1980; R0mer, 1979) , where high SACE is presumably due to increased formation in the monocyte macrophage-derived noncaseating epithelioid granulomas (Silverstein et al., 1979) .
Non-caseating epithelioid granulomas occur in 3-400 of lung cancer patients (Laurberg, 1975) . In some cases this finding can lead to an erroneous diagnosis of sarcoidosis (R0mer, 1980b Although at present the clinical use of SACE measurement has been restricted to sarcoidosis, the present results indicate a significant and perhaps useful relationship between SACE and prognosis in lung cancer, because a low SACE seems to indicate poor prognosis. Thus, measurement of SACE may be a biochemical marker of cancer mass, as has been pro-posed for carcinoembryonic antigen (Concannon et al., 1978; Dent et al., 1978) . The present findings suggest that if a patient with lung cancer has a very low SACE, one should re-evaluate the patient with respect to operability, even if he has been judged as being operable by conventional criteria.
